A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
Clinical trial NCT06237335 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06237335
- Sponsor
- ReCode Therapeutics
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-01
- Primary completion
- 2026-11-01
- Enrollment
- 128
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.